Skip to main content
. 2023 Jul 7;14:1190663. doi: 10.3389/fphar.2023.1190663

TABLE 3.

Safety assessment reported by volunteers within 2 months of the trial.

Symptoms All (n = 50) Control (n = 25) 250 mg OPP (n = 25) p
None reported 7 5 2 0.417
Bloated 1 0 1 1.000
Easy to defecate 13 6 7 0.747
Get hungry easily 9 5 4 1.000
Lightheaded 4 2 2 1.000
Lose weight easily 5 3 2 1.000
More energetic 7 3 4 1.000
Reduce menstrual pain 1 0 1 1.000
Short menstrual duration 2 0 2 0.490
Sleepiness 1 1 0 1.000

Data are tabulated as frequency, n (%).